Ranbaxy Shifts Lipitor Generic Production From U.S. To New India Plant
This article was originally published in PharmAsia News
Ranbaxy Laboratories has begun transferring U.S. production of its generic version of Pfizer’s Lipitor (atorvastatin) cholesterol drug back home to India at its newly approved production facility in Mohali.
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.